Iceland
Icelandic Medicines Agency (Lyfjastofnun) (IMA)
Iceland regulates pharmaceutical products through the Icelandic Medicines Agency — Lyfjastofnun (IMA) — under the Medicinal Products Act (Lyfjalög nr. 100/2020) and is fully aligned with EU pharmaceutical legislation as a member of the European Economic Area (EEA) via the EFTA Agreement. EMA Centralised Procedure decisions taken by the European Commission are mirrored in Iceland by an EEA Joint Committee decision and a parallel national IMA decision, typically within 30 days of the EU decision. DCP, MRP and national procedures are handled by IMA directly. Iceland is a non-voting observer at EMA committees (CHMP, PRAC, CAT, COMP, PDCO, HMPC) and a full participant in CMDh; it is a PIC/S member and a member of the Nordic Pharmaceutical Forum (with Sweden MPA, Norway DMP, Denmark DKMA, Finland Fimea). Despite its small population (~390,000), Iceland is a fully functioning regulator with a particular pragmatic approach to access — the small market often relies on Nordic partners, accepts multilingual Nordic packs, and operates flexible exemption routes for unregistered medicines. The dossier follows EU eCTD; English is fully accepted for assessment, with Icelandic required for SmPC (Samantekt á eiginleikum lyfs / SmPC), PIL (fylgiseðill) and labelling for products marketed in Iceland (with practical exemptions for low-volume products via Nordic packs or English labelling waivers). Reimbursement and pricing are administered by Sjúkratryggingar Íslands (Icelandic Health Insurance / SÍ) for outpatient prescription medicines, with the Lyfjagreiðslunefnd (Drug Pricing Committee / LGN) setting maximum wholesale and retail prices via international reference pricing (against Nordic countries plus selected EU benchmarks). Hospital medicines are funded by Landspítali (the National University Hospital) and other regional hospitals, with HTA-style assessment increasingly informed by Nordic collaboration (FINOSE — joint Nordic HTA between Finland, Norway, Sweden, plus Iceland and Denmark observer status — and the EU HTA Coordination Group).
About the authority
Lyfjastofnun (IMA) is Iceland's competent authority for human and veterinary medicines, medical devices, narcotics control and pharmacy oversight. Headquartered in Reykjavík (Vínlandsleið 14), it reports to the Ministry of Health (Heilbrigðisráðuneytið) and is led by a Director-General (forstjóri). IMA covers marketing authorisation, GMP/GDP inspection (under PIC/S), pharmacovigilance, clinical trial authorisation under the EU CTR via CTIS, narcotics licensing, medical device oversight, and exemption authorisations for unregistered medicines (undanþágulyf — exemption-licensed medicines, a distinctive Icelandic feature). IMA participates as observer in EMA committees and as a full member in CMDh; it is a frequent CMS in DCP and MRP procedures and occasionally acts as RMS for Nordic-market generics.
International affiliations
Reliance & recognition
Iceland is fully integrated into the EU regulatory network as an EEA Member State via the EFTA Agreement. EMA centralised authorisations are mirrored in Iceland through an EEA Joint Committee decision (~30 days after the EC decision) and a parallel IMA national MA. DCP and MRP enable cross-recognition with EU/EEA partners. IMA collaborates very closely with Nordic regulators (Sweden MPA, Norway DMP, Denmark DKMA, Finland Fimea) under the Nordic Pharmaceutical Forum, including joint Nordic generics assessments, shared inspections and pragmatic acceptance of Nordic-language labelling. Outside the EU/EEA framework, Iceland does not operate a standalone reliance pathway for non-EU SRA decisions.
Compare Iceland side-by-side
Benchmark timelines, fees and pathway requirements against another market.
Other Europe markets
Same structure. Same source-citation standard.